Sandra Steffens

Author PubWeight™ 6.64^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.	Eur J Cancer	2012	1.08
2	Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?	Int J Urol	2012	0.89
3	Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma.	BMC Cancer	2013	0.87
4	Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder.	Med Oncol	2013	0.83
5	Corpulence is the crucial factor: association of testosterone and/or obesity with prostate cancer stage.	Int J Urol	2014	0.78
6	Renal Cell Carcinoma Update: News from the AUA, EAU, and ASCO Annual Meetings 2011.	ISRN Urol	2012	0.78
7	Positive surgical margins in nephron-sparing surgery: risk factors and therapeutic consequences.	World J Surg Oncol	2014	0.78
8	Arteriolar vascular smooth muscle cell differentiation in benign nephrosclerosis.	Nephrol Dial Transplant	2012	0.77
9	Trophoblast Cell Surface Antigen 2 (Trop2) in Chromophobe Renal Cell Carcinoma.	Oncology	2022	0.75
10	Capsulotomy for treatment of compartment syndrome in patients with post extracorporeal shock wave lithotripsy renal hematomas: safe and effective, but also advisable?	Urol J	2014	0.75